JP Morgan Chase’s Ultragenyx Pharmaceutical RARE Stock Holding History

JP Morgan Chase’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-89,600	Closed	-$2.06M	–	7822
2025 Q4	$2.06M	Buy	89,600 +67,700	+309%	+$2.23M	﹤0.01%	4047
2025 Q3	$659K	Sell	21,900 -95,600	-81%	-$2.87M	﹤0.01%	4864
2025 Q2	$4.27M	Buy	117,500 +66,500	+130%	+$2.4M	﹤0.01%	3299
2025 Q1	$1.85M	Buy	51,000 +21,000	+70%	+$874K	﹤0.01%	3941
2024 Q4	$1.26M	Buy	+30,000	New	+$1.49M	﹤0.01%	4459
2024 Q3	–	Sell	-35,000	Closed	-$1.44M	–	7626
2024 Q2	$1.44M	Hold	35,000	–	–	﹤0.01%	4018
2024 Q1	$1.63M	Buy	+35,000	New	+$1.65M	﹤0.01%	4000
2019 Q2	–	Sell	-95,000	Closed	-$6.59M	–	5961
2019 Q1	$6.59M	Buy	+95,000	New	+$5.43M	﹤0.01%	2363
2018 Q3	–	Sell	-30,000	Closed	-$2.31M	–	5788
2018 Q2	$2.31M	Buy	+30,000	New	+$1.94M	﹤0.01%	3310

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

JP Morgan Chase's RARE Position: Q2 2026 in Review

JP Morgan Chase increased its Ultragenyx Pharmaceutical (RARE) stake by 101% in Q2 2026, buying an estimated $6.14M and bringing the position to 493,126 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2442.

JP Morgan Chase first reported a position in RARE in Q1 2014 and has held it in 50 quarters since. The position peaked at $121M in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

JP Morgan Chase held 493,126 shares of Ultragenyx Pharmaceutical worth $15.3M as of Q2 2026.
JP Morgan Chase bought 247,198 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $6.14M.
Ultragenyx Pharmaceutical made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2442 holding.
JP Morgan Chase first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 50 quarters since.
JP Morgan Chase's Ultragenyx Pharmaceutical position peaked at $121M in Q3 2025.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.